Kathleen Sebelius - 26 Aug 2021 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role: Director
Signature: /s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact
Issuer symbol: HUMA
Transactions as of: 26 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 27 Aug 2021, 16:11:14 UTC
Previous filing: 02 Jul 2021
Next filing: 15 Oct 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HUMA	Stock Options (right to buy)	Award		+39,389			39,389	26 Aug 2021	Common Stock	39,389	$2.56	Direct	F1, F2
transaction	HUMA	Stock Options (right to buy)	Award		+17,068			17,068	26 Aug 2021	Common Stock	17,068	$6.54	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options are fully vested and exercisable.
F2	On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.

Content

Options are fully vested and exercisable.

On August 26, 2021, Alpha Healthcare Acquisition Corp. ("AHAC") consummated a business combination (the "Business Combination") by and among AHAC, Hunter Merger Sub, Inc., a Delaware corporation ("Hunter Merger Sub") and Humacyte, Inc., a Delaware corporation ("Legacy Humacyte"), AHAC changed its name to "Humacyte, Inc." and Hunter Merger Sub merged with and into Legacy Humacyte. As part of the Business Combination, each Legacy Humacyte stock option was exchanged for a stock option to acquire 0.2626 shares of common stock of Humacyte, Inc.